This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Lithium hydroxide
- DrugBank Accession Number
- DB14506
- Background
Used for tryptophan determinations in proteins & foods.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
Structure for Lithium hydroxide (DB14506)
- Weight
- Average: 23.95
Monoisotopic: 24.01874309 - Chemical Formula
- HLiO
- Synonyms
- Lithium hydrate
- Lithium hydroxide anhydrous
- Lithiumhydroxid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAceclofenac Aceclofenac may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level. Acetazolamide The absorption of Lithium hydroxide can be decreased when combined with Acetazolamide. Acetophenazine Lithium hydroxide may increase the neurotoxic activities of Acetophenazine. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Lithium hydroxide monohydrate G51XLP968G 1310-66-3 GLXDVVHUTZTUQK-UHFFFAOYSA-M - Active Moieties
Name Kind UNII CAS InChI Key Lithium cation ionic 8H8Z5UER66 7439-93-2 HBBGRARXTFLTSG-UHFFFAOYSA-N - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Lithium Hydroxide Monohydrate Solution 8 meq/5mL Oral Morton Grove Pharmaceuticals, Inc. 1986-05-21 2011-04-06 US 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 903YL31JAS
- CAS number
- 1310-65-2
- InChI Key
- WMFOQBRAJBCJND-UHFFFAOYSA-M
- InChI
- InChI=1S/Li.H2O/h;1H2/q+1;/p-1
- IUPAC Name
- lithium(1+) hydroxide
- SMILES
- [Li+].[OH-]
References
- General References
- Not Available
- External Links
- ChemSpider
- 3802
- 1546375
- ChEBI
- 33979
- Wikipedia
- Lithium_hydroxide
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Oral 8 meq/5mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 0 Chemaxon pKa (Strongest Acidic) 3.09 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 109.0211 predictedDeepCCS 1.0 (2019) [M+H]+ 110.90915 predictedDeepCCS 1.0 (2019) [M+Na]+ 118.29976 predictedDeepCCS 1.0 (2019)
Drug created at July 11, 2018 21:53 / Updated at June 02, 2024 21:54